Think Bioscience raises $55M in oversubscribed Series A
PR Newswire—Think Bioscience, a CU Boulder biotechnology spinout focused on unlocking elusive drug targets, has raised $55M in an oversubscribed Series A. Returning investors include AV8 Ventures, CU Innovations and Buff Gold Ventures.
The University of Colorado Connection
Think Bioscience is a Boulder-based synthetic biology company with strong roots at CU Boulder. The company was spun out of Jerome Fox 's lab (CU Boulder Department of Chemical and Biological Engineering and BioFrontiers Institute), where its foundational technology, leveraging microbial systems to discover small-molecule drugs for previously “undruggable” targets, was developed. Its lead programs, including inhibitors of PTP1B, emerged directly from this academic research.
The Newsroom
For marketing and communication inquiries or news tips, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.